• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and Translational Allergy >Basophils response to Pru p 3 and Ara h 9 in patients sensitised to peach under specific immunotherapy
【24h】

Basophils response to Pru p 3 and Ara h 9 in patients sensitised to peach under specific immunotherapy

机译：在特异性免疫疗法下对桃子敏感的患者，嗜碱性粒细胞对Pru p 3和Ara h 9的反应

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

RationaleIn Southern Europe Pru p3 is the primary sensitizer ofplants fruit and it is responsible of severe reactions.Specific immunotherapy (SIT) brings a new perspectiveto treat those patients. There is a lack of knowledgeregarding cellular responses that include changes in thebasophil activation during the IT. We aim to analyseearly changes in the basophil response to Pru p 3 andother related allergen (Ara h 9) after the first month ofsublingual immunotherapy (SLIT).MethodsForty-six peach allergic patients confirmed by positivespecific IgE determined by skin prick test or fresh peach(prick-by-prick), ImmunoCAP IgE and/or a double blindplacebo control food challenge with peach. Basophilreactivity was determined by the basophil activation test(BAT) with Pru p 3 and Ara h 9 at two concentrations,1 and 0.1 μg/ml, before and after 1month of SLIT.ResultsTwenty one patients evaluated (45%) performed anaphylaxisand 25 (55%) urticaria and/or angioedema. The82,6% showed sensitization to other plant foods proteinsand 69,5% showed sensitization to pollens. The BATwas done in 25 patients with first month of SLIT completed.The 28% patients have an increase of Pru p 3reactivity. The 36% patients showed same reactivity afterfirst month and 36% presented a decreased reactivity toPru p3. Similar results were obtained for Ara h 9 inthose patients.ConclusionPreliminary result disclosed that percentage of patientswho underwent changes in BAT reactivity to Pru p3and Ara h 9 was similar. There have been no differentialclinical pattern in the groups studied after one month ofSLIT. The BAT shows a good correlation between bothPru p 3 and Ara h 9.
机译：原理在南欧，Pru p3是植物果实的主要敏化剂，并引起严重的反应。特异性免疫疗法（SIT）为治疗这些患者带来了新的前景。缺乏有关细胞反应的知识，其中包括IT期间嗜碱性粒细胞激活的变化。我们的目的是分析舌下免疫疗法（SLIT）后第一个月后对Pru p 3和其他相关过敏原（Ara h 9）的嗜碱性粒细胞反应的变化。方法46例桃皮过敏患者经皮肤点刺试验或新鲜桃皮检测通过IgE阳性特异性证实一针一针），ImmunoCAP IgE和/或双盲安慰剂对照食物攻击桃子。在SLIT的1个月之前和之后，通过嗜碱性粒细胞活化试验（BAT）用Pru p 3和Ara h 9分别以1和0.1μg/ ml的两种浓度测定嗜碱性粒细胞反应性。结果评价的21例患者（45％）进行了过敏反应和25例（55） ％）荨麻疹和/或血管性水肿。 82.6％的人对其他植物性食物蛋白过敏，而69.5％的人对花粉过敏。在25例SLIT的第一个月完成的患者中完成了BAT.28％的患者的Pru p 3反应性增加。 36％的患者在第一个月后表现出相同的反应性，而36％的患者对Pru p3的反应性降低。对于Ara h 9患者，也获得了类似的结果。结论初步结果显示，接受BAT对Pru p3和Ara h 9反应的患者百分比相似。 SLIT治疗一个月后，各组均无差异临床模式。 BAT显示出Pru p 3和Ara h 9之间的良好相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号